Bionano Genomics reported a 56% increase in publications using optical genome mapping (OGM) for rare disease analysis in Q1 2026 compared to Q1 2025. The number of samples analyzed grew 225%, highlighting OGM's growing role in identifying structural variants missed by traditional methods. Studies from multiple countries show OGM improves diagnosis by resolving previously unexplained genetic cases and complements sequencing techniques. This advancement may accelerate research and treatment options for rare genetic disorders worldwide.

More News (BNGO)

Bionano Genomics highlights 13 studies proving optical genome mapping's value in reproductive and prenatal health research.

Bionano Genomics announced that in 2026, 13 independent studies involving 730 samples demonstrated the effectiveness of optical genome mapping (OGM) in detecting structural genetic variants related to reproductive health and prenatal disorders. These...

Market News

Bullish

4 days ago

Publications on optical genome mapping in rare diseases rise 56% in Q1 2026, boosting genetic diagnosis.

More News (BNGO)

Bionano Genomics highlights 13 studies proving optical genome mapping's value in reproductive and prenatal health research.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Publications on optical genome mapping in rare diseases rise 56% in Q1 2026, boosting genetic diagnosis.

More News (BNGO)

Bionano Genomics highlights 13 studies proving optical genome mapping's value in reproductive and prenatal health research.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App